Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Humans
Male
Female
Middle Aged
Adult
Imatinib Mesylate
/ therapeutic use
Aged
Leukemia, Myeloid, Acute
/ genetics
Translocation, Genetic
Registries
Chromosomes, Human, Pair 22
/ genetics
Fusion Proteins, bcr-abl
/ genetics
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chromosomes, Human, Pair 9
/ genetics
Young Adult
Nucleophosmin
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
02
04
2024
accepted:
14
05
2024
revised:
10
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
31
5
2024
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little data on outcome since the era of tyrosine kinase inhibitors. Among 5819 AML cases included in the DATAML registry, 20 patients with de novo BCR::ABL1
Identifiants
pubmed: 38821940
doi: 10.1038/s41408-024-01069-9
pii: 10.1038/s41408-024-01069-9
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Fusion Proteins, bcr-abl
EC 2.7.10.2
NPM1 protein, human
0
Nucleophosmin
117896-08-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Informations de copyright
© 2024. The Author(s).
Références
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.
doi: 10.1182/blood.2022015850
pubmed: 35767897
pmcid: 9479031
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Neuendorff NR, Burmeister T, Dörken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol. 2016;95:1211–21.
doi: 10.1007/s00277-016-2721-z
pubmed: 27297971
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
doi: 10.1182/blood-2009-11-254441
pubmed: 20385793
Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013;54:138–44.
doi: 10.3109/10428194.2012.701739
pubmed: 22691121
Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7:5122–31.
doi: 10.1182/bloodadvances.2023010173
pubmed: 37327116
pmcid: 10477447
Orsmark-Pietras C, Landberg N, Lorenz F, Uggla B, Höglund M, Lehman S, et al. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study. Genes Chromosomes Cancer. 2021;60:426–33.
doi: 10.1002/gcc.22936
pubmed: 33433047
Eisfeld AK, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211–8.
doi: 10.1038/leu.2017.86
pubmed: 28321123
pmcid: 5628133
Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol. 2013;161:541–50.
doi: 10.1111/bjh.12301
pubmed: 23521501
Boucher L, Sorel N, Desterke C, Chollet M, Rozalska L, Gallego Hernanz MP, et al. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis. Int J Mol Sci. 2023;24:15441.
doi: 10.3390/ijms242015441
pubmed: 37895120
pmcid: 10607477
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
doi: 10.1182/blood.2022016867
pubmed: 35797463
Vergez F, Largeaud L, Bertoli S, Nicolau ML, Rieu JB, Vergnolle I, et al. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. Blood Cancer J. 2022;12:117.
doi: 10.1038/s41408-022-00712-7
pubmed: 35973983
pmcid: 9381519
Gabert J, Beillard E, van der Velden VH, Bi W, Grimawade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318–57.
doi: 10.1038/sj.leu.2403135
pubmed: 14562125
Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol. 2007;127:642–50.
doi: 10.1309/B4NVER1AJJ84CTUU
pubmed: 17369142
Zhou Q, Zhao D, Eladl E, Capo-Chichi JM, Kim DDH, Chang H. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia. Leuk Res. 2023;124:107002.
doi: 10.1016/j.leukres.2022.107002
pubmed: 36563650
Ozga M, Nicolet D, Mrózek K, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024;38:45–57.
doi: 10.1038/s41375-023-02068-8
pubmed: 38017103
Min GJ, Kim H-J, Yoon J-H, Kwak D-H, Park S-S, Jeon Y-W, et al. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome–Positive Acute Myeloid Leukemia in Adults. Biol Blood Marrow Transplant. 2018;24:1621–8.
doi: 10.1016/j.bbmt.2018.04.020
pubmed: 29698793
Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, et al. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. Bone Marrow Transpl. 2015;50:1586–8.
doi: 10.1038/bmt.2015.206
Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, et al. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2018;93:31–39.
doi: 10.1002/ajh.24928
pubmed: 28971504
Angenendt L, Röllig C, Montesinos P, Martinez-Cuadron D, Barragan E, Garcia R, et al. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. J Clin Oncol. 2019;37:2632–42.
doi: 10.1200/JCO.19.00416
pubmed: 31430225
pmcid: 8462529
Neuendorff NR, Hemmati P, Arnold R, Ihlow J, Dörken B, Müller-Tidow C, et al. BCR-ABL(+) acute myeloid leukemia: are we always dealing with a high-risk disease? Blood Adv. 2018;2:1409–11.
doi: 10.1182/bloodadvances.2018015594
pubmed: 29914972
pmcid: 6020811
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2022;9:e121–32.
doi: 10.1016/S2352-3026(21)00370-7
pubmed: 34906334